EDITAS MEDICINE, INC. Proceeds from Common Stock Issued
EDITAS MEDICINE, INC. (EDIT) reported Proceeds from Common Stock Issued of $117.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-05
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $117.50M, a 1535.57% increase year-over-year.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $17.08M.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $17.15M.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for fiscal 2025 was $42.85M.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for fiscal 2023 was $117.08M.
- EDITAS MEDICINE, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $117.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $117.50M 10-Q · filed 2026-08-05 | $134.58M derived: sum of 3 quarters · filed 2026-08-05 | $151.73M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $17.08M derived: sum of 2 quarters · filed 2026-05-05 | $34.23M derived: sum of 3 quarters · filed 2026-05-05 | $41.41M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $17.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $34.23M derived: sum of 2 quarters · filed 2026-03-09 | $41.41M derived: sum of 3 quarters · filed 2026-08-05 | $42.85M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $17.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $24.33M derived: sum of 2 quarters · filed 2026-08-05 | $25.77M 10-Q · filed 2025-11-10 | $25.77M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $7.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $8.62M 10-Q · filed 2026-08-05 | $8.62M derived: sum of 3 quarters · filed 2026-08-05 | $8.62M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $1.44M 10-Q · filed 2026-05-05 | $1.44M derived: sum of 2 quarters · filed 2026-05-05 | $1.44M derived: sum of 3 quarters · filed 2026-05-05 | $1.44M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | $0.00 derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | $0.00 derived: sum of 3 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $117.08M 10-K · filed 2025-03-05 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $117.08M 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | $117.08M 10-Q · filed 2024-08-07 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 10-K · filed 2025-03-05 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-03 | ||||
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.00K derived: sum of 2 quarters · filed 2024-02-28 | -$10.00K derived: sum of 3 quarters · filed 2024-02-28 | $249.46M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$11.00K derived: sum of 2 quarters · filed 2022-11-02 | $249.46M 10-Q · filed 2022-11-02 | $249.34M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $249.46M 10-Q · filed 2022-08-03 | $249.34M derived: sum of 3 quarters · filed 2023-02-22 | $249.22M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | $249.47M 10-Q · filed 2022-05-04 | $249.36M derived: sum of 2 quarters · filed 2023-02-22 | $249.23M derived: sum of 3 quarters · filed 2023-02-22 | ||
| 2020-12-31 | -$113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$238.00K derived: sum of 2 quarters · filed 2023-02-22 | $203.73M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | -$125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $203.84M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $203.70M 10-K · filed 2021-02-26 | $203.96M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $75.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $116.34M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $41.22M 10-Q · filed 2020-11-06 | ||||
| 2018-12-31 | $28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $28.32M derived: sum of 2 quarters · filed 2021-02-26 | $28.32M derived: sum of 3 quarters · filed 2021-02-26 | $76.79M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$3.00K derived: sum of 2 quarters · filed 2019-11-12 | $48.47M 10-Q · filed 2019-11-12 | $105.93M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $48.47M 10-Q · filed 2019-08-07 | $105.93M derived: sum of 3 quarters · filed 2020-02-26 | $105.93M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | $48.47M 10-Q · filed 2019-05-08 | $105.93M derived: sum of 2 quarters · filed 2020-02-26 | $105.93M derived: sum of 3 quarters · filed 2020-02-26 | $105.52M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | $57.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $57.46M derived: sum of 2 quarters · filed 2020-02-26 | $57.04M derived: sum of 3 quarters · filed 2020-02-26 | $154.14M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$417.00K derived: sum of 2 quarters · filed 2018-11-08 | $96.69M 10-Q · filed 2018-11-08 | $96.69M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | -$417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $96.69M 10-Q · filed 2018-08-07 | $96.69M derived: sum of 3 quarters · filed 2019-03-01 | $96.49M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $97.10M 10-Q · filed 2018-05-04 | $97.10M derived: sum of 2 quarters · filed 2019-03-01 | $96.91M derived: sum of 3 quarters · filed 2019-03-01 | $96.41M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$196.00K derived: sum of 2 quarters · filed 2019-03-01 | -$694.00K derived: sum of 3 quarters · filed 2019-03-01 | $97.49M 10-K · filed 2019-03-01 | |
| 2016-09-30 | -$196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$694.00K derived: sum of 2 quarters · filed 2017-11-08 | $97.49M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $97.68M 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | $98.18M 10-Q · filed 2017-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |